DK1446162T3 - Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet - Google Patents

Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet

Info

Publication number: DK1446162T3
Authority: DK; Denmark
Prior art keywords: nucleic acids; enhanced activity; immunostimulatory oligonucleotides; combination motif; class
Prior art date: 2001-08-17

Application number

DK02768621T

Other languages

English (en)

Inventor

Arthur M Krieg

Joerg Vollmer

Eugen Uhlmann

Original Assignee

Coley Pharm Gmbh

Univ Iowa Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-17

Filing date

2002-08-19

Publication date

2008-12-08

2002-08-19 Application filed by Coley Pharm Gmbh, Univ Iowa Res Found filed Critical Coley Pharm Gmbh

2008-12-08 Application granted granted Critical

2008-12-08 Publication of DK1446162T3 publication Critical patent/DK1446162T3/da

Links

230000003308 immunostimulating effect Effects 0.000 title abstract 3
108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000000694 effects Effects 0.000 title 1
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000039446 nucleic acids Human genes 0.000 abstract 3
108020004707 nucleic acids Proteins 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000035473 Communicable disease Diseases 0.000 abstract 1
102000014150 Interferons Human genes 0.000 abstract 1
108010050904 Interferons Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000000172 allergic effect Effects 0.000 abstract 1
208000010668 atopic eczema Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
229940079322 interferon Drugs 0.000 abstract 1
210000000822 natural killer cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Analytical Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK02768621T 2001-08-17 2002-08-19 Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet DK1446162T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US31327301P	2001-08-17	2001-08-17
US39395202P	2002-07-03	2002-07-03
PCT/US2002/026468 WO2003015711A2 (en)	2001-08-17	2002-08-19	Combination motif immune stimulatory oligonucleotides with improved activity

Publications (1)

Publication Number	Publication Date
DK1446162T3 true DK1446162T3 (da)	2008-12-08

Family

ID=26978772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02768621T DK1446162T3 (da)	2001-08-17	2002-08-19	Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet

Country Status (22)

Country	Link
US (1)	US8834900B2 (da)
EP (1)	EP1446162B1 (da)
JP (2)	JP4383534B2 (da)
KR (1)	KR100991644B1 (da)
CN (1)	CN1604795B (da)
AT (1)	ATE411054T1 (da)
AU (1)	AU2002331643B2 (da)
BR (1)	BR0211962A (da)
CA (1)	CA2457485C (da)
CY (1)	CY1109398T1 (da)
DE (1)	DE60229422D1 (da)
DK (1)	DK1446162T3 (da)
EA (1)	EA007232B1 (da)
ES (1)	ES2314099T3 (da)
IL (2)	IL160157A0 (da)
MX (1)	MXPA04001458A (da)
NZ (2)	NZ552377A (da)
PT (1)	PT1446162E (da)
SG (1)	SG177000A1 (da)
SI (1)	SI1446162T1 (da)
WO (1)	WO2003015711A2 (da)
ZA (1)	ZA200401531B (da)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP0855184A1 (en)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU760549B2 (en) *	1998-04-03	2003-05-15	University Of Iowa Research Foundation, The	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU761899B2 (en) *	1998-05-22	2003-06-12	Ottawa Health Research Institute	Methods and products for inducing mucosal immunity
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
WO2000048630A1 (en)	1999-02-17	2000-08-24	Csl Limited	Immunogenic complexes and methods relating thereto
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
NZ517929A (en) *	1999-09-25	2004-02-27	Univ Iowa Res Found	Immunostimulatory nucleic acids
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
AU2001227889A1 (en)	2000-01-14	2001-07-24	The United States of America, represented by The Secretary, Department of Health & Human Services	Oligodeoxynucleotide and its use to induce an immune response
WO2001095935A1 (en) *	2000-01-20	2001-12-20	Ottawa Health Research Institute	Immunostimulatory nucleic acids for inducing a th2 immune response
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
AU7013401A (en) *	2000-06-22	2002-01-02	Univ Iowa Res Found	Methods for enhancing antibody-induced cell lysis and treating cancer
WO2002022809A2 (en) *	2000-09-15	2002-03-21	Coley Pharmaceutical Gmbh	PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
EP1350262B8 (en) *	2000-12-08	2008-08-13	Coley Pharmaceuticals GmbH	Cpg-like nucleic acids and methods of use thereof
DE60142410D1 (de)	2000-12-27	2010-07-29	Dynavax Tech Corp	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
ES2487645T3 (es) *	2001-06-21	2014-08-22	Dynavax Technologies Corporation	Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) *	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
PT1446162E (pt)	2001-08-17	2009-01-27	Coley Pharm Gmbh	Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada
WO2003031573A2 (en) *	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Toll-like receptor 3 signaling agonists and antagonists
CA2462203A1 (en) *	2001-10-12	2003-11-20	University Of Iowa Research Foundation	Methods and products for enhancing immune responses using imidazoquinoline compounds
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
EP1499187B1 (en)	2002-04-04	2015-06-17	Zoetis Belgium S.A.	Immunostimulatory g,u-containing oligoribonucleotides
AU2003243409A1 (en) *	2002-06-05	2003-12-22	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
CA2494508A1 (en) *	2002-07-03	2004-01-15	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) *	2002-07-17	2004-02-02	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
US8263091B2 (en)	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004039829A2 (en) *	2002-10-29	2004-05-13	Coley Pharmaceutical Group, Ltd.	Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP1578954A4 (en) *	2002-12-11	2010-08-11	Coley Pharm Group Inc	5'-CPG NUCLEIC ACIDS AND USE METHOD
ES2328807T3 (es) *	2002-12-23	2009-11-18	Dynavax Technologies Corporation	Secuencia de oligonucleotidos inmunoestimuladores y metodos para usar los mismos.
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
BRPI0411514A (pt) *	2003-06-20	2006-08-01	Coley Pharm Gmbh	antagonistas de receptor toll-like de molécula pequena
AU2004275876B2 (en)	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
OA13278A (en) *	2003-10-30	2007-01-31	Coley Pharm Gmbh	C-Class oligonucleotide analogs with enhanced immunostimulatory potency.
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
US9090673B2 (en) *	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
KR100558851B1 (ko) *	2004-01-08	2006-03-10	학교법인연세대학교	면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
CA2572427A1 (en) *	2004-07-18	2006-01-18	Heather L. Davis	Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
EP1899467A2 (en) *	2005-04-26	2008-03-19	Coley Pharmaceutical GmbH	Modified oligoribonucleotide analogs with enhances immunostimulatory activity
WO2007062107A2 (en) *	2005-11-25	2007-05-31	Coley Pharmaceutical Gmbh	Immunostimulatory oligoribonucleotides
WO2007095316A2 (en)	2006-02-15	2007-08-23	Coley Pharmaceutical Gmbh	Compositions and methods for oligonucleotide formulations
KR101065760B1 (ko)	2006-05-31	2011-09-19	오사카 유니버시티	면역자극 올리고뉴클레오티드 및 그 의약 용도
WO2007143582A2 (en) *	2006-06-05	2007-12-13	Baylor College Of Medicine	Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
CN101517082B (zh)	2006-09-27	2014-01-22	科勒制药有限责任公司	具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
WO2008139262A2 (en) *	2006-10-26	2008-11-20	Coley Pharmaceutical Gmbh	Oligoribonucleotides and uses thereof
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
BRPI0811621A2 (pt)	2007-05-17	2014-10-21	Coley Pharm Group Inc	Oligonucleotídeos de classe a com potência imunoestimuladora, composição contendo os mesmos e uso da referida composição
HRP20150769T1 (hr) *	2007-05-18	2015-08-28	Adiutide Pharmaceuticals Gmbh	Oligonukleotidni analozi s modificiranim fosfatima, s imunostimulirajuä†om aktivnošä†u
SI2179039T1 (sl)	2007-08-13	2019-01-31	Zoetis Belgium S.A.	Motivi RNA-zaporedja v kontekstu definiranih mednukleotidnih vezi, ki inducirajo specifične imunsko modulacijske profile
CA2696460A1 (en) *	2007-08-13	2009-02-19	Pfizer Inc.	Combination motif immune stimulatory oligonucleotides with improved activity
CN101820908A (zh) *	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物
KR101333852B1 (ko)	2008-06-27	2013-11-27	조에티스 엘엘씨	신규한 면역증강 조성물
US9061001B2 (en)	2008-10-16	2015-06-23	University Of Saskatchewan	Combination adjuvant formulation
JP6066035B2 (ja) *	2009-02-12	2017-01-25	クルナ・インコーポレーテッド	グリア細胞由来神経栄養因子（ｇｄｎｆ）関連疾病の、ｇｄｎｆに対する天然アンチセンス転写物の抑制による治療
AU2010229835B2 (en)	2009-03-25	2015-01-15	The Board Of Regents Of The University Of Texas System	Compositions for stimulation of mammalian innate immune resistance to pathogens
CA2757620C (en)	2009-04-30	2016-04-26	Coley Pharmaceutical Group, Inc.	Pneumococcal vaccine and uses thereof
JP2011251963A (ja)	2010-05-28	2011-12-15	Coley Pharmaceutical Group Inc	抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
MX374682B (es)	2010-09-09	2025-03-06	Pfizer	Moléculas de unión a 4-1bb.
DK2640426T3 (da) *	2010-11-16	2016-05-02	Selecta Biosciences Inc	Immunstimulerende oligonukleotider
EP2471926A3 (en) *	2010-12-30	2012-07-11	Intervet International BV	Immunostimulatory oligodeoxynucleotides
WO2012160183A1 (en) *	2011-05-26	2012-11-29	Intervet International B.V.	Immunostimulatory oligodeoxynucleotides
CA2837207A1 (en)	2011-06-01	2012-12-06	Janus Biotherapeutics, Inc.	Novel immune system modulators
RU2606114C2 (ru)	2011-06-01	2017-01-10	Джейнус Байотерапьютикс, Инк.	Новые модуляторы иммунной системы
IN2014KN00948A (da)	2011-10-04	2015-08-21	Janus Biotherapeutics Inc
US12268718B2 (en)	2012-01-16	2025-04-08	Labyrinth Holdings Llc	Control of cellular redox levels
CA2860311A1 (en)	2012-01-16	2013-07-25	Elizabeth Mckenna	Compositions and methods for the treatment of hepatitic diseases and disorders
JP2014012650A (ja) *	2012-07-05	2014-01-23	Nihon Univ	上皮バリア機能の増強方法及び増強剤
US9617547B2 (en)	2012-07-13	2017-04-11	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant
WO2014047588A1 (en)	2012-09-21	2014-03-27	Elizabeth Mckenna	Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
BR112016005948A2 (pt)	2013-09-19	2017-09-26	Zoetis Services Llc	adjuvantes com base em óleo
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108046A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JP2017525711A (ja)	2014-08-22	2017-09-07	ジャナスバイオセラピューティクス，インク．	新規なｎ２，ｎ４，ｎ７，６−四置換プテリジン−２，４，７−トリアミンおよび２，４，６，７−四置換プテリジン化合物ならびにその合成方法および使用
US10286065B2 (en)	2014-09-19	2019-05-14	Board Of Regents, The University Of Texas System	Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US10682365B2 (en)	2014-12-31	2020-06-16	Checkmate Pharmaceuticals, Inc.	Combination tumor immunotherapy
AR103427A1 (es)	2015-01-16	2017-05-10	Zoetis Services Llc	Vacuna contra la fiebre aftosa
US20190030153A1 (en)	2015-07-22	2019-01-31	University Of Saskatchewan	Mycoplasma vaccines and uses thereof
EP3436066A1 (en)	2016-04-01	2019-02-06	Checkmate Pharmaceuticals, Inc.	Fc receptor-mediated drug delivery
US11173207B2 (en)	2016-05-19	2021-11-16	The Regents Of The University Of Michigan	Adjuvant compositions
EP3576786A1 (en)	2017-01-31	2019-12-11	Alf Lamprecht	Use of nanoparticles for immunotherapy
CN111511762B (zh)	2017-08-21	2025-05-06	天演药业公司	抗cd137分子及其用途
WO2019148444A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en)	2018-02-02	2019-08-08	Adagene Inc.	Precision/context-dependent activatable antibodies, and methods of making and using the same
EP3752194A4 (en)	2018-02-13	2022-03-16	Checkmate Pharmaceuticals, Inc.	ANTI-TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS
WO2019197965A1 (en)	2018-04-09	2019-10-17	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
WO2019224715A1 (en)	2018-05-23	2019-11-28	Pfizer Inc.	Antibodies specific for cd3 and uses thereof
TWI803637B (zh)	2018-05-23	2023-06-01	美商輝瑞大藥廠	特異性針對gucy2c之抗體及其用途
US20220370606A1 (en)	2018-12-21	2022-11-24	Pfizer Inc.	Combination Treatments Of Cancer Comprising A TLR Agonist
MX2021010320A (es)	2019-02-28	2021-11-12	Sqz Biotechnologies Co	Administracion de biomoleculas a celulas mononucleares de sangre periferica (pbmc) para modificar una respuesta inmunitaria.
CA3164623A1 (en)	2019-12-17	2021-06-24	Pfizer Inc.	Antibodies specific for cd47, pd-l1, and uses thereof
CA3176303A1 (en)	2020-04-20	2021-10-28	Antonio FACCIUOLO	Compositions and methods for preventing, controlling and diagnosing mycobacterial infections
US20230133118A1 (en)	2020-05-13	2023-05-04	Adagene Ag	Compositions and methods for treating cancer
CA3202218A1 (en)	2020-12-18	2022-06-23	Century Therapeutics, Inc.	Chimeric antigen receptor systems with adaptable receptor specificity
JP2024534858A (ja) *	2021-08-31	2024-09-26	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	インターフェロン誘導性の複合体およびｒｎａ二重鎖ならびに使用方法
KR102730717B1 (ko) *	2021-09-02	2024-11-14	세종대학교산학협력단	미토콘드리아 dna 매개 면역 증강 유도용 구아닌/시토신 기반 포스포로티오에이트 결합 줄기-고리 구조 올리고데옥시뉴클레오타이드
WO2023081813A1 (en)	2021-11-05	2023-05-11	St. Jude Children's Research Hospital, Inc.	Zip cytokine receptors
WO2023240182A1 (en)	2022-06-08	2023-12-14	St. Jude Children's Research Hospital, Inc.	Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en)	2022-09-16	2024-03-21	St. Jude Children's Research Hospital, Inc.	Disruption of asxl1 in t cells to enhance immunotherapy
WO2025015118A1 (en) *	2023-07-11	2025-01-16	Rutgers, The State University Of New Jersey	Pharmaceutical compositions and methods for treating fungal infections

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US384480A (en) *		1888-06-12		Signor to the faebweeke
US3854480A (en)	1969-04-01	1974-12-17	Alza Corp	Drug-delivery system
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4675189A (en)	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
AU561343B2 (en)	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
EP0092574B1 (en)	1981-10-23	1992-04-29	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and methods of making same
US4452775A (en)	1982-12-03	1984-06-05	Syntex (U.S.A.) Inc.	Cholesterol matrix delivery system for sustained release of macromolecules
US4806463A (en)	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en)	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en)	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
CA1339596C (en)	1987-08-07	1997-12-23	New England Medical Center Hospitals, Inc.	Viral expression inhibitors
US5004810A (en)	1988-09-30	1991-04-02	Schering Corporation	Antiviral oligomers
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5457189A (en)	1989-12-04	1995-10-10	Isis Pharmaceuticals	Antisense oligonucleotide inhibition of papillomavirus
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5514788A (en)	1993-05-17	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of cell adhesion
US5514577A (en)	1990-02-26	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide therapies for modulating the effects of herpes viruses
US5248670A (en)	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
US5166195A (en)	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
DE69128350T2 (de)	1990-06-11	1998-03-26	Nexstar Pharmaceuticals Inc	Nukleinsäureliganden
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
DE69126710T2 (de)	1990-08-16	1998-01-15	Isis Pharmaceutical, Inc., Carlsbad, Calif.	Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen
WO1994008003A1 (en)	1991-06-14	1994-04-14	Isis Pharmaceuticals, Inc.	ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5582986A (en)	1991-06-14	1996-12-10	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide inhibition of the ras gene
US5407686A (en)	1991-11-27	1995-04-18	Sidmak Laboratories, Inc.	Sustained release composition for oral administration of active ingredient
US6498147B2 (en)	1992-05-22	2002-12-24	The Scripps Research Institute	Suppression of nuclear factor-κb dependent processes using oligonucleotides
JPH08501928A (ja)	1992-07-02	1996-03-05	ハイブライドンインコーポレイテッド	治療剤としての自己安定化オリゴヌクレオチド
NZ257434A (en)	1992-10-05	1997-01-29	Hybridon Inc	Anti-hiv oligonucleotides having a sequence complementary to at least nucleotides 324-348 of the gag region of hiv-1 and resistance to nuclease digestion and medicaments thereof
US5567604A (en)	1993-04-23	1996-10-22	Aronex Pharmaceuticals, Inc.	Anti-viral guanosine-rich oligonucleotides
HUT74597A (en)	1993-06-23	1997-01-28	Genesys Pharma Inc	Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
KR960704033A (ko)	1993-07-19	1996-08-31	다니엘 엘. 캐시앙	인간 면역결핍 바이러스에 대한 활성을 갖는 올리고뉴클레오티드(Oligonucleotides with Activity against Humand Immunodeficiency Virus)
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
DK0772619T4 (da)	1994-07-15	2011-02-21	Univ Iowa Res Found	Immunmodulatoriske oligonukleotider
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030050263A1 (en)	1994-07-15	2003-03-13	The University Of Iowa Research Foundation	Methods and products for treating HIV infection
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US5646262A (en)	1994-07-28	1997-07-08	Georgetown University	Antisense oligonucleotides against hepatitis B viral replication
US5932556A (en)	1995-09-17	1999-08-03	Tam; Robert C	Methods and compositions for regulation of CD28 expression
GB9505438D0 (en)	1995-03-17	1995-05-03	Sod Conseils Rech Applic	Antisense oligonucleotides
US5736152A (en)	1995-10-27	1998-04-07	Atrix Laboratories, Inc.	Non-polymeric sustained release delivery system
US5780448A (en)	1995-11-07	1998-07-14	Ottawa Civic Hospital Loeb Research	DNA-based vaccination of fish
US6030955A (en)	1996-03-21	2000-02-29	The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc.	Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof
ATE292980T1 (de)	1996-10-11	2005-04-15	Univ California	Immunostimulierende oligonucleotidekonjugate
CA2278031A1 (en)	1996-12-27	1998-07-09	Robert Tam	G-rich oligo aptamers and methods of modulating an immune response
EP0855184A1 (en)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US20030064945A1 (en)	1997-01-31	2003-04-03	Saghir Akhtar	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
EP1039935A4 (en)	1997-02-28	2005-04-27	Univ Iowa Res Found	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en)	1997-03-10	2002-10-24	Ottawa Civic Loeb Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6835395B1 (en)	1997-05-14	2004-12-28	The University Of British Columbia	Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
CA2289741A1 (en)	1997-05-19	1998-11-26	Merck & Co., Inc.	Oligonucleotide adjuvant
CA2301575C (en)	1997-05-20	2003-12-23	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en)	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999001154A1 (en)	1997-07-03	1999-01-14	University Of Iowa Research Foundation	Method for inhibiting immunostimulatory dna associated responses
US5877309A (en)	1997-08-13	1999-03-02	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides against JNK
JP4663113B2 (ja)	1997-09-05	2011-03-30	ザリージェンツオブザユニバーシティオブカリフォルニア	抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
US20050031638A1 (en)	1997-12-24	2005-02-10	Smithkline Beecham Biologicals S.A.	Vaccine
CA2323524A1 (en)	1998-03-27	1999-10-07	Immunex Corporation	Nk cell activation inducing ligand (nail) dna and polypeptides, and use thereof
AU760549B2 (en)	1998-04-03	2003-05-15	University Of Iowa Research Foundation, The	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en)	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
AU760795B2 (en)	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
AU761899B2 (en)	1998-05-22	2003-06-12	Ottawa Health Research Institute	Methods and products for inducing mucosal immunity
US6881561B1 (en)	1998-05-27	2005-04-19	Cheil Jedang Corporation	Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
ES2226414T3 (es)	1998-06-10	2005-03-16	Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh	Estimulacion del sistema inmunitario.
US20040247662A1 (en)	1998-06-25	2004-12-09	Dow Steven W.	Systemic immune activation method using nucleic acid-lipid complexes
WO2000006588A1 (en)	1998-07-27	2000-02-10	University Of Iowa Research Foundation	STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
EP0979869A1 (en)	1998-08-07	2000-02-16	Hoechst Marion Roussel Deutschland GmbH	Short oligonucleotides for the inhibition of VEGF expression
WO2000014217A2 (en)	1998-09-03	2000-03-16	Coley Pharmaceutical Gmbh	G-motif oligonucleotides and uses thereof
US20020065236A1 (en)	1998-09-09	2002-05-30	Yew Nelson S.	CpG reduced plasmids and viral vectors
FR2783170B1 (fr)	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
FR2790955B1 (fr)	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
AU4343700A (en)	1999-04-12	2000-11-14	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Oligodeoxynucleotide and its use to induce an immune response
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
EP1177439B1 (en)	1999-04-29	2004-09-08	Coley Pharmaceutical GmbH	Screening for immunostimulatory dna functional modifiers
AP1891A (en)	1999-05-06	2008-09-23	The Immune Response Corp	HIV immunogenic compositions and methods.
CA2376634A1 (en)	1999-06-08	2000-12-14	Aventis Pasteur	Immunostimulant oligonucleotide
CA2412345A1 (en)	1999-06-16	2000-12-21	University Of Iowa Research Foundation	Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
DE19935756A1 (de)	1999-07-27	2001-02-08	Mologen Forschungs Entwicklung	Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
NZ517929A (en) *	1999-09-25	2004-02-27	Univ Iowa Res Found	Immunostimulatory nucleic acids
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
WO2001022990A2 (en)	1999-09-27	2001-04-05	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2593701A (en)	1999-12-21	2001-07-03	Regents Of The University Of California, The	Method for preventing an anaphylactic reaction
WO2001095935A1 (en)	2000-01-20	2001-12-20	Ottawa Health Research Institute	Immunostimulatory nucleic acids for inducing a th2 immune response
WO2001055370A2 (en) *	2000-01-26	2001-08-02	Hybridon, Inc.	MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805265B1 (fr)	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
US20020156033A1 (en)	2000-03-03	2002-10-24	Bratzler Robert L.	Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en)	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
AU7013401A (en)	2000-06-22	2002-01-02	Univ Iowa Res Found	Methods for enhancing antibody-induced cell lysis and treating cancer
US20020165178A1 (en)	2000-06-28	2002-11-07	Christian Schetter	Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en)	2000-08-01	2002-12-26	Bratzler Robert L.	Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en)	2000-09-07	2002-07-11	Bratzler Robert L.	Nucleic acids for the prevention and treatment of sexually transmitted diseases
WO2002022809A2 (en)	2000-09-15	2002-03-21	Coley Pharmaceutical Gmbh	PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
FR2814958B1 (fr)	2000-10-06	2003-03-07	Aventis Pasteur	Composition vaccinale
GB0025577D0 (en)	2000-10-18	2000-12-06	Smithkline Beecham Biolog	Vaccine
EP1350262B8 (en)	2000-12-08	2008-08-13	Coley Pharmaceuticals GmbH	Cpg-like nucleic acids and methods of use thereof
US20030055014A1 (en)	2000-12-14	2003-03-20	Bratzler Robert L.	Inhibition of angiogenesis by nucleic acids
DE60142410D1 (de)	2000-12-27	2010-07-29	Dynavax Tech Corp	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US20030050268A1 (en)	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
ES2487645T3 (es)	2001-06-21	2014-08-22	Dynavax Technologies Corporation	Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos
WO2003012061A2 (en)	2001-08-01	2003-02-13	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
JP4607452B2 (ja)	2001-08-07	2011-01-05	ダイナバックステクノロジーズコーポレイション	免疫調節性組成物、製剤およびその使用方法
PT1446162E (pt)	2001-08-17	2009-01-27	Coley Pharm Gmbh	Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada
WO2003031573A2 (en)	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Toll-like receptor 3 signaling agonists and antagonists
CA2462203A1 (en)	2001-10-12	2003-11-20	University Of Iowa Research Foundation	Methods and products for enhancing immune responses using imidazoquinoline compounds
US6838227B2 (en) *	2001-11-30	2005-01-04	Seagate Technology Llc	Polystyrene as a resist for making patterned media
EP1499187B1 (en)	2002-04-04	2015-06-17	Zoetis Belgium S.A.	Immunostimulatory g,u-containing oligoribonucleotides
AU2003243409A1 (en)	2002-06-05	2003-12-22	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en)	2002-07-17	2004-02-02	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
WO2004026888A2 (en)	2002-09-19	2004-04-01	Coley Pharmaceutical Gmbh	Toll-like receptor 9 (tlr9) from various mammalian species
WO2004039829A2 (en)	2002-10-29	2004-05-13	Coley Pharmaceutical Group, Ltd.	Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
EP1578954A4 (en)	2002-12-11	2010-08-11	Coley Pharm Group Inc	5'-CPG NUCLEIC ACIDS AND USE METHOD
ES2328807T3 (es)	2002-12-23	2009-11-18	Dynavax Technologies Corporation	Secuencia de oligonucleotidos inmunoestimuladores y metodos para usar los mismos.
AU2004226605A1 (en)	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
EP1631687A2 (en)	2003-04-22	2006-03-08	Coley Pharmaceutical GmbH	Methods and products for identification and assessment of tlr ligands
BRPI0411514A (pt)	2003-06-20	2006-08-01	Coley Pharm Gmbh	antagonistas de receptor toll-like de molécula pequena
AU2004275876B2 (en)	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
US20050215501A1 (en)	2003-10-24	2005-09-29	Coley Pharmaceutical Group, Inc.	Methods and products for enhancing epitope spreading
OA13278A (en)	2003-10-30	2007-01-31	Coley Pharm Gmbh	C-Class oligonucleotide analogs with enhanced immunostimulatory potency.
US20050239733A1 (en)	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en)	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
KR100558851B1 (ko)	2004-01-08	2006-03-10	학교법인연세대학교	면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체
WO2005097993A2 (en)	2004-02-19	2005-10-20	Coley Pharmaceutical Group, Inc.	Immunostimulatory viral rna oligonucleotides
US20060019916A1 (en)	2004-04-02	2006-01-26	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for inducing IL-10 responses
CA2567789A1 (en)	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
WO2006134423A2 (en)	2004-07-18	2006-12-21	Coley Pharmaceutical Group, Ltd.	Methods and compositions for inducing innate immune responses
CA2572427A1 (en)	2004-07-18	2006-01-18	Heather L. Davis	Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
AU2006216493A1 (en)	2005-02-24	2006-08-31	Coley Pharmaceutical Gmbh	Immunostimulatory oligonucleotides
HRP20070516A2 (en)	2005-04-08	2008-12-31	Coley Pharmaceutical Group	Methods for treating infectious disease exacerbated asthma
EP1899467A2 (en)	2005-04-26	2008-03-19	Coley Pharmaceutical GmbH	Modified oligoribonucleotide analogs with enhances immunostimulatory activity
WO2007062107A2 (en)	2005-11-25	2007-05-31	Coley Pharmaceutical Gmbh	Immunostimulatory oligoribonucleotides
EP1962909A4 (en)	2005-12-20	2012-04-18	Idera Pharmaceuticals Inc	IMMUNOSTIMULATING ACTIVITY OF PALINDROMIC IMMUNOMODULATORY OLIGONUCLEOTIDES (IMO TM) CONTAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS
WO2007095316A2 (en)	2006-02-15	2007-08-23	Coley Pharmaceutical Gmbh	Compositions and methods for oligonucleotide formulations
US8027888B2 (en)	2006-08-31	2011-09-27	Experian Interactive Innovation Center, Llc	Online credit card prescreen systems and methods
WO2008033432A2 (en)	2006-09-12	2008-03-20	Coley Pharmaceutical Group, Inc.	Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
JP2010504982A (ja)	2006-09-27	2010-02-18	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｔｌｒのリガンドと抗ウイルス剤との組成物
CN101517082B (zh)	2006-09-27	2014-01-22	科勒制药有限责任公司	具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
WO2008139262A2 (en)	2006-10-26	2008-11-20	Coley Pharmaceutical Gmbh	Oligoribonucleotides and uses thereof

2002
- 2002-08-19 PT PT02768621T patent/PT1446162E/pt unknown
- 2002-08-19 IL IL16015702A patent/IL160157A0/xx unknown
- 2002-08-19 EP EP02768621A patent/EP1446162B1/en not_active Expired - Lifetime
- 2002-08-19 AU AU2002331643A patent/AU2002331643B2/en not_active Ceased
- 2002-08-19 BR BR0211962-5A patent/BR0211962A/pt not_active Application Discontinuation
- 2002-08-19 EA EA200400319A patent/EA007232B1/ru not_active IP Right Cessation
- 2002-08-19 CA CA2457485A patent/CA2457485C/en not_active Expired - Lifetime
- 2002-08-19 ES ES02768621T patent/ES2314099T3/es not_active Expired - Lifetime
- 2002-08-19 JP JP2003520672A patent/JP4383534B2/ja not_active Expired - Fee Related
- 2002-08-19 DE DE60229422T patent/DE60229422D1/de not_active Expired - Lifetime
- 2002-08-19 MX MXPA04001458A patent/MXPA04001458A/es active IP Right Grant
- 2002-08-19 NZ NZ552377A patent/NZ552377A/en not_active IP Right Cessation
- 2002-08-19 US US10/224,523 patent/US8834900B2/en not_active Expired - Fee Related
- 2002-08-19 SG SG2006010128A patent/SG177000A1/en unknown
- 2002-08-19 CN CN028182138A patent/CN1604795B/zh not_active Expired - Fee Related
- 2002-08-19 DK DK02768621T patent/DK1446162T3/da active
- 2002-08-19 NZ NZ531194A patent/NZ531194A/en not_active IP Right Cessation
- 2002-08-19 WO PCT/US2002/026468 patent/WO2003015711A2/en not_active Ceased
- 2002-08-19 KR KR1020047002289A patent/KR100991644B1/ko not_active Expired - Fee Related
- 2002-08-19 AT AT02768621T patent/ATE411054T1/de active
- 2002-08-19 SI SI200230776T patent/SI1446162T1/sl unknown
2004
- 2004-02-01 IL IL160157A patent/IL160157A/en unknown
- 2004-02-25 ZA ZA2004/01531A patent/ZA200401531B/en unknown
2008
- 2008-10-03 JP JP2008259120A patent/JP2009028051A/ja not_active Withdrawn
- 2008-12-03 CY CY20081101400T patent/CY1109398T1/el unknown

Also Published As

Publication number	Publication date
WO2003015711A2 (en)	2003-02-27
EP1446162A2 (en)	2004-08-18
WO2003015711A3 (en)	2004-06-10
EA007232B1 (ru)	2006-08-25
DE60229422D1 (de)	2008-11-27
EP1446162B1 (en)	2008-10-15
CA2457485A1 (en)	2003-02-27
KR100991644B1 (ko)	2010-11-02
ATE411054T1 (de)	2008-10-15
JP4383534B2 (ja)	2009-12-16
SG177000A1 (en)	2012-01-30
CN1604795A (zh)	2005-04-06
EP1446162A4 (en)	2005-02-16
HK1067547A1 (en)	2005-04-15
PT1446162E (pt)	2009-01-27
AU2002331643B2 (en)	2007-10-11
MXPA04001458A (es)	2005-02-17
CN1604795B (zh)	2010-05-26
BR0211962A (pt)	2005-04-19
NZ531194A (en)	2007-02-23
ZA200401531B (en)	2005-05-25
CY1109398T1 (el)	2014-07-02
SI1446162T1 (sl)	2009-04-30
JP2005502338A (ja)	2005-01-27
WO2003015711A9 (en)	2003-04-10
US8834900B2 (en)	2014-09-16
CA2457485C (en)	2012-08-14
ES2314099T3 (es)	2009-03-16
IL160157A0 (en)	2004-07-25
KR20040036714A (ko)	2004-04-30
NZ552377A (en)	2008-08-29
IL160157A (en)	2010-11-30
JP2009028051A (ja)	2009-02-12
EA200400319A1 (ru)	2004-12-30
US20030148976A1 (en)	2003-08-07

Publication	Publication Date	Title
DK1446162T3 (da)	2008-12-08	Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
EP1417351A4 (en)	2005-06-01	ANTISENSE MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN (A)
NO20025508D0 (no)	2002-11-15	Substituerte tioacetamider
EP1417216A4 (en)	2005-11-09	ANTISENSE MODULATION OF BCL2 ASSOCIATED X-PROTEIN EXPRESSION
CY1108240T1 (el)	2014-02-12	ΑΠΟΜΟΝΩΜΕΝΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΤΑ ΟΠΟΙΑ ΕΧΟΥΝ ΕΝΑ ΜΕΙΩΜΕΝΟ ΠΕΡΙΕΧΟΜΕΝΟ ΜΟΤΙΒΩΝ 5΄CpG3΄ ΕΠΙΓΕΝΕΤΙΚΟΥ ΕΛΕΓΧΟΥ ΚΑΙ ΟΙ ΧΡΗΣΕΙΣ ΤΟΥΣ
EA200100700A1 (ru)	2001-12-24	Гены и белки и их применение
DE69833876D1 (de)	2006-05-11	Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
WO2001045738A3 (en)	2001-12-27	Use of heat shock proteins to enhance production of chemokines by a cell
EP1248635A4 (en)	2004-12-08	ANTISENSE MODULATION OF THE GLYCOGEN SYNTHASE-KINASE-3ALPHA EXPRESSION
EA200100701A1 (ru)	2001-12-24	Белки наружной поверхности, их гены и их применение
WO2003040161A3 (en)	2005-06-02	Antisense modulation of activating transcription factor 3 expression
DE60135232D1 (de)	2008-09-18	Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
EP1397516A4 (en)	2005-05-11	ANTISENSE MODULATION OF THE EXPRESSION OF THE P40 SUBUNIT OF INTERLEUKIN 12
TR199800850T2 (xx)	1998-09-21	Kan� d�zenleyici bile�imler.
WO2001075026A3 (fr)	2002-01-03	Nouveau polypeptide, eucaryote acetyl transferase humaine 10, et polynucleotide codant pour ce polypeptide
WO2001075046A3 (fr)	2002-03-28	Nouveau polypeptide, gene humain de regulation 17 du cycle mitotique, et polynucleotide codant pour ce polypeptide
WO2001094540A3 (en)	2002-04-04	A novel polypeptide, a human glucosyl hydrolase 23 and the polynucleotide encoding the polypeptide
WO2001075001A3 (en)	2002-03-07	A novel polypeptide, cyclic adenosine 9-dependant human protein kinase and the polynucleotide encoding the polypeptide
WO2001075002A3 (fr)	2002-01-24	Nouveau polypeptide, gène de regulation du cycle cellulaire humain 28, et polynucléotide codant pour ce polypeptide
TH12544S1 (th)	2002-04-24	กะละมัง
TH42362S (th)	2001-01-10	กะละมัง
IT1316533B1 (it)	2003-04-22	Struttura di elettrovalvola, particolarmente per prodotti del settoredell'idromassaggio.
TH48760S (th)	2001-12-25	เครื่องควบคุมอุณหภูมิ
TH14942S1 (th)	2003-07-09	เครื่องควบคุมอุณหภูมิ
TH26817S1 (th)	2009-10-15	ผ้าอนามัย